Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA
March 12, 2024 09:00 ET | Nacuity Pharmaceuticals, Inc.
REYKJAVIK, Iceland and FORT WORTH, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Arctic Therapeutics ehf, an Icelandic drug development company and partner Nacuity Pharmaceuticals, Inc., a...
Reports and Data.jpeg-01
Next Generation Sequencing Market To Reach USD 19.12 Billion By 2026 | Reports And Data
September 18, 2019 13:34 ET | Reports and Data
New York, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Government initiatives for large scale NGS based projects, collaborations for technical advancements in NGS and declining costs are key factors...
New Life Scientific, Inc. to Present at the ValueRich Small Cap Financial Exposition -- September 15, 2005
September 01, 2005 06:20 ET | New Life Scientific Inc.
FREEHOLD, N.J., Sept. 1, 2005 (PRIMEZONE) -- New Life Scientific, Inc. ("New Life") (OTCBB:NWLF), an emerging bio-tech company, today announced that it will be a presenting company...
SmallCap Sentinel Logo
SmallCap Sentinel: Gauging the Impact of the Pending Horde of Baby Boomers
August 29, 2005 03:30 ET | SmallCap Sentinel
IRVINE, Calif., Aug. 29, 2005 (PRIMEZONE) -- "While many fear the lack of investment dollars in the stock market by retiring baby boomers, savvy investors are focusing on the areas where this...
Galapagos Announces Half Year 2005 Results
August 12, 2005 02:24 ET | Galapagos Genomics
Mechelen, Belgium, Aug. 12, 2005 (PRIMEZONE) -- Galapagos: - Financials on target for 2005 increased annual revenues and cash burn of around 7 million euro - Initial public offering...
Keryx Logo Side Icon.jpg
Keryx Biopharmaceuticals to Present at Banc of America Securities Annual Health Care Conference
May 17, 2005 08:29 ET | Keryx Biopharmaceuticals, Inc.
NEW YORK, May 17, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the...
Galapagos Appoints Andre Hoekema as Managing Director Galadeno
April 12, 2005 05:07 ET | Crucell N.V.
LEIDEN, Netherlands, April 12, 2005 (PRIMEZONE) -- Galapagos, a genomics-based drug discovery company, has appointed Dr. Andre Hoekema as Managing Director of Galadeno, Galapagos' services unit....
Actelion Ltd: Japanese Approval for Tracleer(r) in PAH
April 11, 2005 01:31 ET | Actelion Ltd.
ALLSCHWIL, Switerzerland, April 11, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that the Japanese Ministry of Health, Labor and Welfare has granted formal approval...
Crucell and DSM Announce PER.C6(R) Licensing and Service Agreement with Roche for Protein Production
February 16, 2005 02:13 ET | Crucell N.V.
LEIDEN, The Netherlands, Feb. 16, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they...
Crucell Fully Compliant
January 26, 2005 07:38 ET | Crucell N.V.
LEIDEN, The Netherlands, Jan. 26, 2005 (PRIMEZONE) -- In media coverage today a suggestion was made that insider trading occurred on the exercise of options on January 18, 2005, by certain employees...